Cytomegalovirus Retinitis in a Patient Taking Upadacitinib: A Case Report

被引：4

作者：

Hirai, Hiromasa ^{[1
]}

Akai, Yasuhiro ^{[2
]}

Ogata, Nahoko ^{[1
]}

Ueda, Tetsuo ^{[1
]}

机构：

[1] Nara Med Univ, Ophthalmol, Kashihara, Japan

[2] Nara Med Univ, Community Med, Rheumatol, Kashihara, Japan

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2023年 / 15卷 / 11期

关键词：

jak inhibitor; rheumatoid arthritis; upadacitinib; cytomegalovirus (cmv); cytomegalovirus retinitis; UVEITIS;

D O I：

10.7759/cureus.48337

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Upadacitinib is a relatively new drug used to treat autoimmune diseases. However, patients treated with upadacitinib may develop infections. We report a case of cytomegalovirus (CMV) retinitis that developed during upadacitinib administration. A 79-year-old woman presented with progressively decreasing vision in both eyes. Her decimal best-corrected visual acuity (BCVA) was 0.2 in the right and 0.01 in the left eye. The patient was taking upadacitinib for one year. Fundus examination revealed vitreous opacities and extensive white retinal lesions with hemorrhage in both eyes. CMV was detected in the anterior aqueous humor, vitreous humor, and blood samples. We diagnosed her with panuveitis and CMV retinitis, performed a vitrectomy in both eyes, and administered intravenous ganciclovir and steroids. After treatment, her BCVA improved to 0.6 in the right and 0.1 in the left eye. Ophthalmologists and physicians should be aware of CMV infections in patients being treated with upadacitinib.

引用

页数：4

共 17 条

[1]

Biggioggero Martina, 2019, Drugs Context, V8, P212595, DOI [10.7573/dic.212595, 10.7573/dic.212595]

[2] Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials [J].